We are a pre-clinical stage biotech company developing first-in-class small molecules to induce mitophagy, i.e. the process of replacing damaged mitochondria. We address age-related and chronic diseases including CNS disorders to treat cognitive impairment.
Products, services, technology
We are developing small molecules to treat unmet medical need in the areas of CNS, lung, liver, and muscle disease. Our frontrunner CNS compound will enter clinical development by year-end 2024.
Cooperation possibilities
We are looking for potential investors for our Series B fundraise and for pharma partners for our research and development platform covering CNS, lung, liver, and muscle diseases.
- https://vandria.com/
- +41 76 615 27 26
- info@vandria.com
- Marko Milo
Some insights
We are trying to address unmet medical need in areas of high demand such as Alzheimer's Disease and age-related muscle wasting.
Within a short time since incorporation, we are already on the verge of becoming a clinical-stage biotech company. This was only possible due to our highly skilled and very diverse team.
The core strengths of our team relate to the understanding of mitochondrial biology incl. mitophagy and the clinical development of novel medicines addressing unmet medical need. For the future, we are looking for skills in the field of project management and regulatory services.
That we are trying to develop novel treatments for patients that currently do not have many options to cope with their diseases such as Alzheimer's Disease or age-related muscle wasting.
By helping us to make connections to potential investors, potential partners from the pharmaceutical industry and to identify top vendors required for drug development.